Drugs / NY-ESO-1 peptide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05479045 | Sep 2026 → Nov 2027 | ovarian carcinoma, uterine adnexa cancer | Georgetown University | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1 peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05479045 ↗ |
| Modality | Vaccine | “NY-ESO-1 peptide vaccine” NCT05479045 ↗ |